Poly Medicure has scheduled its 31st Annual General Meeting (AGM) for September 5, 2026. The company published a formal notice in a newspaper to inform shareholders of the upcoming event and the matters requiring their consideration.

The notice was digitally signed by Avinash Chandra on August 15, 2026, at 4:39 pm. The document serves as a statutory communication to ensure all equity shareholders are aware of the meeting date and the specific resolutions to be voted upon.

Agenda Details

The advertisement outlines the standard procedural items for the annual meeting. While the specific text of the resolutions is obscured in the provided draft, typical AGM agendas include the adoption of financial statements, appointment of auditors, and declaration of dividends if approved by the board.

Shareholders are expected to review these items during the meeting. The company must adhere to regulatory timelines for dispatching notices and holding the assembly as per the Companies Act requirements.

Corporate Governance

This filing represents a routine corporate governance obligation rather than a disclosure of operational or financial performance. Poly Medicure will likely release its quarterly or annual financial results separately through stock exchange filings.

Investors should monitor subsequent communications from the company for updates on revenue, profit, and strategic initiatives following the conclusion of the AGM.

Poly Medicure Limited reported mixed financial results for the first quarter of FY26, with consolidated revenue surging 25.6% year-on-year while net profit declined 8.4%. The company’s standalone performance showed marginal growth, indicating that the divergence in top-line and bottom-line figures is primarily driven by its subsidiaries. The results were announced on August 10, 2026, following board approval on August 7, 2026.

Consolidated revenue from operations jumped to ₹55,878.45 lakh in Q1FY26, compared to ₹44,490.16 lakh in Q1FY25. Despite this significant top-line expansion, consolidated net profit after tax fell to ₹8,527.43 lakh from ₹9,308.29 lakh in the corresponding period last year. Standalone revenue grew more modestly by 8.1% to ₹45,974.91 lakh, with standalone net profit rising slightly by 0.2% to ₹8,812.33 lakh.

Financial Performance Highlights

The disparity between the robust revenue growth and declining consolidated profits suggests increased operational costs or lower margins in the subsidiary segments during the quarter. Standalone earnings per share (EPS) remained stable at ₹8.69, up from ₹8.68 in Q1FY25. However, consolidated diluted EPS dropped to ₹8.48 from ₹9.17 in the previous year’s quarter.

What the Numbers Show

The data reveals a clear divergence between the parent company and the group’s overall performance. While Poly Medicure’s standalone operations maintained profitability with steady EPS, the consolidated decline in profit despite a 25.6% revenue surge indicates that the subsidiaries contributed disproportionately to costs or faced margin compression. The pre-tax profit before exceptional items for the consolidated entity was ₹11,730.57 lakh, down from ₹12,294.63 lakh in Q1FY25, confirming that the profit drop is not due to tax variations but operational factors within the group structure.

The unaudited results were reviewed by the Audit Committee and approved by the Board of Directors. Statutory auditors have limited reviewed the financial statements. The full format results are available on the stock exchange websites and the company’s investor relations page.